<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794844</url>
  </required_header>
  <id_info>
    <org_study_id>744230</org_study_id>
    <nct_id>NCT02794844</nct_id>
  </id_info>
  <brief_title>Implementation of PPI Medication PGX Testing</brief_title>
  <acronym>PGX</acronym>
  <official_title>Implementation of Pharmacogenomic Testing in Nemours Children's Health System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nemours Children's Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using genetic information about the individual to pick the right drug for the right disease
      at the right dose defines personalized medicine. This pilot study seeks to institute
      pharmacogenomic testing, that is identifying genetic variation that influences patient
      response to drugs, into the Nemours Children's Health system. We propose to initiate the
      study by identifying genetic differences in cyp2c19, a gene that is responsible for a certain
      enzyme in the liver that metabolizes many drugs including a class of drugs called proton pump
      inhibitors (ppi; Prevacid, Nexium). PPIs are used to treat heartburn and other symptoms of
      gastroesophageal reflux disease (gerd) and are extensively used in pediatrics. Chronic use of
      PPIs can cause serious side effects including cold, pneumonia and stomach infections, which
      gets worse at higher doses. Children who poorly metabolize drugs because of genetic variation
      in cyp2c19 should get lower doses of PPIs than children who metabolize PPIs normally. Our
      pilot study will genotype children with gerd or other stomach acid mediated conditions for
      which a PPI is prescribed using a sample of spit to determine which dose of PPI they get
      based on the form of the cyp2c19 gene they have. We will study 120 children 2-17 yo diagnosed
      with gastroesophageal reflux disease (gerd) or other stomach acid mediated conditions for
      which a ppi is prescribed . Genetic results are available in &lt; 60 minutes, and their doses
      are determined by their doctor based on genetic results. This study will allow us to gain
      valuable experience that will be used to expand our genetic program to other genes and drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long-term objective of this research is to implement pharmacogenomic (PGX) testing of
      approved gene-drug pairs to maximize the efficacy and minimize adverse events for drugs that
      are used to treat childhood disease. Personalized medicine, that is, the use of the patient's
      own genetic information to predict the right dose of the right drug, has been a goal of
      medicine's since the publication of the human genome and HAPMAP projects. However, the
      adoption of PGX testing has been slow owing to several barriers and challenges. Recently
      President Obama announced the precision medicine initiative, which includes PGX testing, and
      has earmarked $ 1 b to implement it. The precision medicine initiative is expected to move
      personalized medicine forward so that most patients including pediatric patients will
      benefit. The Nemours Children's Health System is uniquely positioned to lead the effort to
      personalize medicine among pediatric patients. The goal of the proposed 1-year pilot project
      is to implement PGX testing in the Nemours children's health system. The experience,
      knowledge and skills gained in this pilot project will position Nemours to help lead
      precision medicine initiatives including PGX testing among pediatric populations. To
      implement PGX testing in Nemours we propose to begin testing the cyp2c19 - proton pump
      inhibitor gene-drug pair in the division of gastroenterology, Nemours children's hospital. A
      total of 120 children 2-17 yo who have been diagnosed with gastroesophageal reflux disease
      (GERD) or other stomach acid mediated conditions for which a PPI is prescribed will be
      recruited into the study by pediatric gastroenterologists (aim 1a). Drs. Franciosi and Lima
      will educate staff in the division of PGX testing and of the study. GI pediatricians are not
      required to participate in PGX testing. After obtaining consent, the study coordinator will
      obtain and bar code samples of saliva from the patient. Samples will be genotyped by Spartan
      Rx, a point-of-care genotyping platform, which are housed (2 of them) in the division of
      pathology. Loss-of-function alleles (*2, *3) and the gain-of-function allele (*17) are
      identified in &lt; 60 minutes. The result of genotyping will be checked by dr. Badizadegan and
      entered into the patient's EMR. Clinical Decision Support (CDS) tools will advise Drs.
      Badizadegan and Franciosi of the patient's metabolic phenotype based on cyp2c19 genotype. Dr.
      Franciosi (or other GI pediatricians) will decide the dose of PPI to use based CDS tools
      carrying algorithms for conventional dosing and for genotype-guided dosing of PPIs. The
      electronic prescription for the PPI with genotype-guided dosing will be called in. PPI
      efficacy and safety for each study participant will be monitored weekly (aim 1B) by
      collecting and recording scores on validated GERD and adverse reaction questionnaires.
      Efficacy and safety scores will be communicated by each participant (or caregiver) using
      mobile devices (iPhone; computer) and recorded using redcap. Dr. Blake will supervise this
      phase of the study. Outcome metrics for aim 1A include: % of patients agreeing to volunteer
      for the study; % of patients reporting efficacy and toxicity data; % of providers agreeing to
      participate in study; and % of participants agreeing to future use of DNA. Outcome metrics
      for aim B will be judgments by Dr. Franciosi and his staff regarding success based on scores
      from GERD and adverse event questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 21, 2016</start_date>
  <completion_date type="Anticipated">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 23, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Patients Agreeing to Volunteer for the Study</measure>
    <time_frame>Through 12 months study</time_frame>
    <description>Outcomes for evaluating the success of PGX implementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Patients Reporting Efficacy and Toxicity Data</measure>
    <time_frame>Throughout 12 month study</time_frame>
    <description>Outcomes for evaluating the success of PGX implementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Providers Agreeing to Participate in Study</measure>
    <time_frame>Throughout 12 month study</time_frame>
    <description>Outcomes for evaluating the success of PGX implementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Agreeing to Future Use of DNA</measure>
    <time_frame>Throughout 12 month study</time_frame>
    <description>Outcomes for evaluating the success of PGX implementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Effects After Genotype-guided PPI Therapy</measure>
    <time_frame>Throughout 12 month study</time_frame>
    <description>Percent of participants reporting adverse effects after genotype-guided PPI therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in Clinical Symptoms After Genotype-guided PPI Therapy.</measure>
    <time_frame>Throughout 12 month study</time_frame>
    <description>Percent of participants reporting an increase in clinical symptoms after genotype-guided PPI therapy.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Genotype Guided PPI Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.
No other ARM will be studied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genotype Guided PPI Dosing</intervention_name>
    <description>Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
    <arm_group_label>Genotype Guided PPI Dosing</arm_group_label>
    <other_name>Prilosec</other_name>
    <other_name>Nexium</other_name>
    <other_name>Prevacid</other_name>
    <other_name>Proton Pump Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children diagnosed with Gastroesophageal Reflux Disease (GERD) or a stomach acid
             mediated condition for which a PPI is prescribed.

          -  Currently taking or will be prescribed Proton Pump Inhibitor (PPI) medication

          -  Parents/legal guardians and or child must also have access to the internet and a valid
             email address to complete weekly required forms.

        Exclusion Criteria:

          -  Children who have had peptic ulcer surgery;

          -  with a history of PKU

          -  with a history of previous adverse effects from PPI treatment or a sensitivity to
             aspartame (NutraSweet, Equal);

          -  who are non-adherent including inability or unwillingness of the legal guardian to
             provide consent of unwillingness of the child to provide assent;

          -  who are unable to take study medications;

          -  who are unable to communicate via telephone or other device;

          -  who do not have access to a computer with internet access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James P Franciosi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemours Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2016</study_first_posted>
  <results_first_submitted>April 9, 2018</results_first_submitted>
  <results_first_submitted_qc>April 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2018</results_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nemours Children's Clinic</investigator_affiliation>
    <investigator_full_name>James Franciosi</investigator_full_name>
    <investigator_title>Principle Research Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proton Pump Inhibitors</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From 06/16/2015 to 02/20/2017, patients (or in the case of children, the pediatric patient and their parent/legal guardian) were approached for participation after a clinical assessment was performed by a GI provider during an outpatient GI appointment. Study procedures were performed after obtaining proper consent and/or child assent.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Genotype Guided PPI Dosing</title>
          <description>Genotype Guided PPI Dosing: PPI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.
No other ARM will be studied.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Genotype Guided PPI Dosing</title>
          <description>Genotype Guided PPI Dosing: PPI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.
No other ARM will be studied.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metabolizer Phenotype Frequency</title>
          <description>Depending on the CYP2C19 genotype individuals are classified into different phenotypes: poor metabolizer (PM), intermediate metabolizers (IM), normal metabolizers (NM), rapid metabolizer (RM) and ultra-rapid metabolizers (UM).</description>
          <population>Results were inconclusive for 5 participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Slow Metabolizers (IM and PM)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal Metabolizers (NM)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fast Metabolizers (EM and UM)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Patients Agreeing to Volunteer for the Study</title>
        <description>Outcomes for evaluating the success of PGX implementation</description>
        <time_frame>Through 12 months study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype Guided PPI Dosing</title>
            <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.
No other ARM will be studied.
Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Agreeing to Volunteer for the Study</title>
          <description>Outcomes for evaluating the success of PGX implementation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Patients Reporting Efficacy and Toxicity Data</title>
        <description>Outcomes for evaluating the success of PGX implementation</description>
        <time_frame>Throughout 12 month study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype Guided PPI Dosing</title>
            <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.
No other ARM will be studied.
Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Reporting Efficacy and Toxicity Data</title>
          <description>Outcomes for evaluating the success of PGX implementation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Providers Agreeing to Participate in Study</title>
        <description>Outcomes for evaluating the success of PGX implementation</description>
        <time_frame>Throughout 12 month study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype Guided PPI Dosing</title>
            <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.
No other ARM will be studied.
Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Providers Agreeing to Participate in Study</title>
          <description>Outcomes for evaluating the success of PGX implementation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Agreeing to Future Use of DNA</title>
        <description>Outcomes for evaluating the success of PGX implementation</description>
        <time_frame>Throughout 12 month study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype Guided PPI Dosing</title>
            <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.
No other ARM will be studied.
Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Agreeing to Future Use of DNA</title>
          <description>Outcomes for evaluating the success of PGX implementation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Effects After Genotype-guided PPI Therapy</title>
        <description>Percent of participants reporting adverse effects after genotype-guided PPI therapy.</description>
        <time_frame>Throughout 12 month study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype Guided PPI Dosing</title>
            <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.
No other ARM will be studied.
Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects After Genotype-guided PPI Therapy</title>
          <description>Percent of participants reporting adverse effects after genotype-guided PPI therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Increase in Clinical Symptoms After Genotype-guided PPI Therapy.</title>
        <description>Percent of participants reporting an increase in clinical symptoms after genotype-guided PPI therapy.</description>
        <time_frame>Throughout 12 month study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype Guided PPI Dosing</title>
            <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.
No other ARM will be studied.
Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Clinical Symptoms After Genotype-guided PPI Therapy.</title>
          <description>Percent of participants reporting an increase in clinical symptoms after genotype-guided PPI therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Genotype Guided PPI Dosing</title>
          <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.
No other ARM will be studied.
Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James P. Franciosi, MD</name_or_title>
      <organization>Nemours Children's Hospital</organization>
      <phone>407-567-3832</phone>
      <email>jfrancio@nemours.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

